Oxygen sensing and hypoxia signalling pathways in animals: The implications of physiology for cancer

Journal of Physiology

Volumn 591, Issue 8, 2013, Pages 2027-2042

  Ratcliffe, Peter J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MICRORNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER PROGNOSIS; CELL HYPOXIA; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLUCOSE TRANSPORT; HYDROXYLATION; HYPOXIA; KIDNEY CARCINOMA; NEOPLASM; NONHUMAN; OXYGEN SENSING; OXYGEN TENSION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANOXIA; DIOXYGENASES; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; OXYGEN; SIGNAL TRANSDUCTION;

EID: 84876325985     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.251470     Document Type: Article

References (130)

1. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchin M, Jain RK, Plate KH & Carmeliet P (2005). Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8, 131-141.
2. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M, Fischer R, Carmeliet P, Maxwell PH, Pugh CW, Frizzell N, Soga T, Kessler BM, El-Bahrawy M, Ratcliffe PJ & Pollard PJ (2011). Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524-537.
3. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ & Gleadle JM (2004). Differential function of the prolyl hydroxylases PHD1, PHD2 and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279, 38458-38465.
4. Bachmann S, Le Hir M & Eckardt K-U (1993). Co-localization of erythropoietin messenger RNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41, 335-341.
5. Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall PA, Fandrey J, Wenger RH & Camenisch G (2009). Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38. J Biol Chem 284, 23046-23058.
6. o site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177, 1029-1036.
7. Berk L, Burchenal JH & Castle WB (1949). Erythropoietic effect of cobalt in patients with or without anemia. N Engl J Med 240, 754-761.
8. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S & Pandolfi PP (2006). PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 442, 779-785.
9. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D & Pouyssegur J (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22, 4082-4090.
10. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS & Bergers G (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146.
11. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR & Dewhirst MW (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56, 941-943.
12. Brugarolas J & Kaelin WG Jr (2004). Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10.
13. Bruick RK & McKnight SL (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340.
14. Bunn HF & Poyton RO (1996). Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76, 839-885.
15. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC & Schumacker PT (1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 95, 11715-11720.
16. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ & Brown PO (2006). Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3, e47.
17. Chowdhury R, McDonough MA, Mecinović J, Loenarz C, Flashman E, Hewitson KS, Domene C & Schofield CJ (2009). Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure 17, 981-989.
18. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ & Maher ER (2001). Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10, 1029-1038.
19. Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, Pugh CW, Oldham NJ, Masson N, Schofield CJ & Ratcliffe PJ (2006). Posttranslational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci U S A 103, 14767-14772.
20. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ & Maxwell PH (2000). Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275, 25733-25741.
21. Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, Edelmann M, Cook KM, Cockman ME, Lancaster DE, Kessler BM, Oldham NJ, Ratcliffe PJ & Schofield CJ (2007). Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem 282, 24027-24038.
22. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber H-P, Ferrara N & Johnson RS (2003). HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657.
23. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR & Futreal PA (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363.
24. Dames SA, Martinez-Yamout M, Guzman RND, Dyson HJ & Wright PE (2002). Structural basis for HIF-1α/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci U S A 99, 5271-5276.
25. reg balance by hypoxia-inducible factor 1. Cell 146, 772-784.
26. Diebold I, Flügel D, Becht S, Belaiba RS, Bonello S, Hess J, Kietzmann T & Görlach A (2010). The hypoxia-inducible factor-2α is stabilized by oxidative stress involving NOX4. Antioxid Redox Signal 13, 425-436.
27. Ehrismann D, Flashman E, Genn DN, Mathioudakis N, Hewitson KS, Ratcliffe PJ & Schofield CJ (2007). Studies on the activity of the hypoxia-inducible factor hydroxylases using an oxygen consumption assay. Biochem J 401, 227-234.
28. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ & Schofield CJ (2003). Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1α. J Biol Chem 278, 1802-1806.
29. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian Y-M, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ & Ratcliffe PJ (2001). C. elegans EGL-9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
30. Firth JD, Ebert BL, Pugh CW & Ratcliffe PJ (1994). Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoeitin 3′ enhancer. Proc Natl Acad Sci U S A 91, 6496-6500.
31. Flashman E, Hoffart LM, Hamed RB, Bollinger JM Jr, Krebs C & Schofield CJ (2010). Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen. FEBS J 277, 4089-4099.
32. Foxler DE, Bridge KS, James V, Webb TM, Mee M, Wong SC, Feng Y, Constantin-Teodosiu D, Petursdottir TE, Bjornsson J, Ingvarsson S, Ratcliffe PJ, Longmore GD & Sharp TV (2012). The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol 14, 201-208.
33. Fraisl P, Aragones J & Carmeliet P (2009). Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8, 139-152.
34. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M & Mechta-Grigoriou F (2004). JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118, 781-794.
35. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U & Bondesson M (2005). Hypoxia requires Notch signaling to maintain the undifferentiated cell state. Dev Cell 9, 617-628.
36. Hanahan D & Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
37. Hewitson KS, Lienard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, Oldham NJ, McNeill LA & Schofield CJ (2007). Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 282, 3293-3301.
38. Hewitson KS, McNeill LA, Riordan MV, Tian Y-M, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW & Schofield CJ (2002). Hypoxia inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277, 26351-26355.
39. Hewitson KS & Schofield CJ (2004). The HIF pathway as a therapeutic target. Drug Discov Today 9, 704-711.
40. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI & Myllyharju J (2003). Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor HIF. J Biol Chem 278, 30772-30780.
41. Hirsilä M, Koivunen P, Xu L, Seeley T, Kivirikko KI & Myllyharju J (2005). Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19, 1308-1310.
42. Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG & Vaupel P (1993). Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26, 45-50.
43. Hoffman DL, Salter JD & Brookes PS (2007). Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling. Am J Physiol Heart Circ Physiol 292, H101-H108.
44. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M & Kaelin WG Jr (2001). von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10, 1019-1027.
45. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI & Jones EY (2002). Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975-978.
46. 2-dependent domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95, 7987-7992.
47. Hughes BT & Espenshade PJ (2008). Oxygen-regulated degradation of fission yeast SREBP by Ofd1, a prolyl hydroxylase family member. EMBO J 27, 1491-1501.
48. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Lineham M & Neckers L (2005). HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153.
49. 2 sensing. Science 292, 464-468.
50. 2-regulated prolyl hydroxylation. Science 292, 468-472.
51. Jelkmann W (1992). Erythropoietin: structure, control of production, and function. Physiol Rev 72, 449-489.
52. Jiang B-H, Zheng JZ, Leung SW, Roe R & Semenza GL (1997). Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272, 19253-19260.
53. Jokilehto T, Högel H, Heikkinen P, Rantanen K, Elenius K, Sundström J & Jaakkola PM (2010). Retention of prolyl hydroxylase PHD2 in the cytoplasm prevents PHD2-induced anchorage-independent carcinoma cell growth. Exp Cell Res 316, 1169-1178.
54. 2 sensing and cancer. Nat Rev Cancer 8, 865-873.
55. Kaelin WG Jr & Ratcliffe PJ (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402.
56. Keith B, Johnson RS & Simon MC (2012). HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12, 9-22.
57. Keith B & Simon MC (2007). Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465-472.
58. Knowles HJ, Mole DR, Ratcliffe PJ & Harris AL (2006). Normoxic stabilization of hypoxia-inducible factor-1α by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 66, 2600-2607.
59. Knowles HJ, Raval RR, Harris AL & Ratcliffe PJ (2003). Effect of ascorbate on the activity of hypoxia inducible factor (HIF) in cancer cells. Cancer Res 63, 1764-1768.
60. Koivunen P, Hirsilä M, Kivirikko KI & Myllyharju J (2006). The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J Biol Chem 281, 28712-28720.
61. Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI & Myllyharju J (2007). Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282, 4524-4532.
62. Kondo K, Kim WY, Lechpammer M & Kaelin WG Jr (2003). Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1, 439-444.
63. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC & Huang LE (2004). HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J 23, 1949-1956.
64. Kuiper C, Molenaar IG, Dachs GU, Currie MJ, Sykes PH & Vissers MC (2010). Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res 70, 5749-5758.
65. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA & Ivan M (2007). A microRNA signature of hypoxia. Mol Cell Biol 27, 1859-1867.
66. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML & Bruick RK (2002a). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16, 1466-1471.
67. Lando D, Peet DJ, Whelan DA, Gorman JJ & Whitelaw ML (2002b). Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295, 858-861.
68. Laughner E, Taghavi P, Chiles K, Mahon PC & Semenza GL (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21, 3995-4004.
69. Leichtweiss H-P, Lübbers DW, Weiss C, Baumgärtl N & Reschke W (1969). The oxygen supply of the rat kidney: measurements of intrarenal pO2. Pflugers Arch 309, 328-349.
70. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S & Kaelin WG Jr (2007). Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27, 5381-5392.
71. Loenarz C, Coleman ML, Boleininger A, Schierwater B, Holland PWH, Ratcliffe PJ & Schofield CJ (2011). The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep 12, 63-70.
72. Loenarz C, Mecinović J, Chowdhury R, McNeill LA, Flashman E & Schofield CJ (2009). Evidence for a stereoelectronic effect in human oxygen sensing. Angew Chem Int Ed Engl 48, 1784-1787.
73. Loenarz C & Schofield CJ (2008). Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4, 152-156.
74. Loenarz C & Schofield CJ (2011). Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci 36, 7-18.
75. McNeill LA, Flashman E, Buck MR, Hewitson KS, Clifton IJ, Jeschke G, Claridge TD, Ehrismann D, Oldham NJ & Schofield CJ (2005). Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol Biosyst 1, 321-324.
76. Mahon PC, Hirota K & Semenza GL (2001). FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15, 2675-2686.
77. Majmundar AJ, Wong WJ & Simon MC (2010). Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40, 294-309.
78. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A & Poellinger L (2001). Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550-554.
79. Makino Y, Uenishi R, Okamoto K, Isoe T, Hosono O, Tanaka H, Kanopka A, Poellinger L, Haneda M & Morimoto C (2007). Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem 282, 14073-14082.
80. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ & Maxwell PH (2002). HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor funtion in the nephron. Cancer Cell 1, 459-468.
81. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM & Klausner RD (2002). The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255.
82. Masson N, Singleton RS, Sekirnik R, Trudgian DC, Ambrose LJ, Miranda MX, Tian YM, Kessler BM, Schofield CJ & Ratcliffe PJ (2012). The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep 12, 251-257.
83. Masson N, Willam C, Maxwell PH, Pugh CW & Ratcliffe PJ (2001). Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20, 5197-5206.
84. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, Doe BG, Ferguson DJP, Johnson MH & Ratcliffe PJ (1993a). Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44, 1149-1162.
85. Maxwell PH, Pugh CW & Ratcliffe PJ (1993b). Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen sensing mechanism. Proc Natl Acad Sci U S A 90, 2423-2427.
86. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER & Ratcliffe PJ (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
87. Min J-H, Yang H, Ivan M, Gertler F, Kaelin WG Jr & Pavletich NP (2002). Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889.
88. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J & Ratcliffe PJ (2009). Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284, 16767-16775.
89. Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ & Maher ER (2009). Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res 29, 4337-4343.
90. Nagao M, Ebert BL, Ratcliffe PJ & Pugh CW (1996). Drosophila melanogaster SL2 cells contain a hypoxically inducible DNA binding complex which recognises mammalian HIF-1 binding sites. FEBS Lett 387, 161-166.
91. Necas E & Thorling EB (1972). Unresponsiveness of erythropoietin-producing cells to cyanide. Am J Physiol 222, 1187-1190.
92. O'Flaherty L, Adam J, Heather LC, Zhdanov AV, Chung YL, Miranda MX, Croft J, Olpin S, Clarke K, Pugh CW, Griffiths J, Papkovsky D, Ashrafian H, Ratcliffe PJ & Pollard PJ (2010). Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum Mol Genet 19, 3844-3851.
93. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V & Kaelin WG (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biology 2, 423-427.
94. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ & Simon MC (2007). Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27, 912-925.
95. Pientka FK, Hu J, Schindler SG, Brix B, Thiel A, Joehren O, Fandrey J, Berchner-Pfannschmidt U & Depping R (2012). Oxygen sensing by prolyl-4-hydroxylase PHD2 within the nuclear compartment and the influence of compartimentalisation on HIF-1 signalling. J Cell Sci 125, 5168-5176.
96. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P & Tomlinson IP (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14, 2231-2239.
97. Prabhakar NR & Semenza GL (2012). Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92, 967-1003.
98. Price JC, Barr EW, Tirupati B, Bollinger JM Jr & Krebs C (2003). The first direct characterization of a high-valent iron intermediate in the reaction of an α-ketoglutarate-dependent dioxygenase: a high-spin Fe(IV) complex in taurine/α-ketoglutarate dioxygenase (TauD) from Escherichia coli. Biochemistry 42, 7497-7508.
99. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM & Ratcliffe PJ (1997). Activation of hypoxia inducible factor-1; definition of regulatory domains within the a subunit. J Biol Chem 272, 11205-11214.
100. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njølstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF Jr, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M & Brennan P (2010). Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43, 60-65.
101. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL & Ratcliffe PJ (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25, 5675-5686.
102. Rosenberger C, Mandriota SJ, Jürgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S & Eckardt KU (2002). Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13, 1721-1732.
103. Rossignol F, Vaché C & Clottes E (2002). Natural antisense transcripts of hypoxia-inducible factor 1α are detected in different normal and tumour human tissues. Gene 299, 135-140.
104. Schödel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, Tomlinson IP, Ratcliffe PJ & Mole DR (2012a). Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet 44, 420-425.
105. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ & Mole DR (2012b). High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207-e217.
106. Schofield CJ & Ratcliffe PJ (2004). Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5, 343-354.
107. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB & Gottlieb E (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85.
108. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732.
109. Semenza GL (2010). HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20, 51-56.
110. Semenza GL (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33, 207-214.
111. Semenza GL & Wang GL (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cellular Biol 12, 5447-5454.
112. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S & Kaelin WG Jr (2011). Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 1, 222-235.
113. Smith TG, Robbins PA & Ratcliffe PJ (2008). The human side of hypoxia-inducible factor. Br J Haematol 141, 325-334.
114. Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch G & Wenger RH (2006). Increased proyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. J Biol Chem 281, 23482-23491.
115. Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, Asagiri M, Simon MC, Hoffmann A & Johnson RS (2010). Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis. Genes Dev 24, 491-501.
116. Tan M, Gu Q, He H, Pamarthy D, Semenza GL & Sun Y (2008). SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1α ubiquitination and degradation. Oncogene 27, 1404-1411.
117. Tanimoto K, Makino Y, Pereira T & Poellinger L (2000). Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 19, 4298-4309.
118. Tian Y, Yeoh KK, Lee MK, Ericsson T, Kessler BM, Kramer HB, Edelmann MJ, William C, Pugh CW, Schofield CJ, Ratcliffe PJ (2011). Differential sensitivity of HIF hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 286, 13041-13051.
119. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E & Clerici C (2004). Prolonged hypoxia differentially regulates HIF-1α and HIF-2α expression in lung epithelial cells: implication of HIF-1α natural antisense. J Biol Chem 279, 14871-14878.
120. Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR, Payette J, Holcik M, Pause A & Lee S (2012). An oxygen-regulated switch in the protein synthesis machinery. Nature 486, 126-129.
121. 2 tension measurements. Cancer Res 51, 3316-3322.
122. Vogelstein B & Kinzler KW (1993). The multistep nature of cancer. Trends Genet 9, 138-141.
123. Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N & Chilvers ER (2005). Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med 201, 105-115.
124. 2 tension. Proc Natl Acad Sci U S A 92, 5510-5514.
125. Wang GL & Semenza GL (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90, 4304-4308.
126. 2 signaling during development of Dictyostelium. Development 134, 3349-3358.
127. Wilkins SE, Hyvärinen J, Chicher J, Gorman JJ, Peet DJ, Bilton RL & Koivunen P (2009). Differences in hydroxylation and binding of Notch and HIF-1α demonstrate substrate selectivity for factor inhibiting HIF-1 (FIH-1). Int J Biochem Cell Biol 41, 1563-1571.
128. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CM & Harris AL (2007). Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67, 3441-3449.
129. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS & Kung AL (2009). Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A 106, 4260-4265.
130. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D & Giaccia AJ (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14, 391-396.